Atea Pharmaceuticals, Inc. (AVIR) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon, everybody, and welcome to ATEA Pharmaceuticals' fourth quarter 2024 Financial Results and Business Update conference call. At this time, all participants are in a listen-only mode. Following the formal remarks, we will open the call up for your questions. I would now like to hand the call over to Janaya Barnes, Senior Vice President, Investor Relations and Corporate Communications at ATEA Pharmaceuticals. Ms. Barnes, please proceed. Thank you, Operator. Good afternoon, everyone, and welcome to Atea Pharmaceutical's fourth quarter and full year 2024 financial results and business update conference call. Earlier today, we issued a press release which outlines the topics we plan to discuss. You can access the press release as well as the slides that we'll be reviewing today by going to the investor section of our website at ir.ateafarma.com. With me today from Atea are our Chief Executive Officer and Founder, Dr. John Pierce Amadosi, Chief Development Officer, Dr. Janet Hammond, John Bavrica, our Chief Commercial Officer, Dr. Arantxa Horga, our Chief Medical Officer, and Chief Financial Officer and Executive Vice President of Legal, Andrea Corcoran. They will all be available for the Q&A portion of today's call. Before we begin the call, and as outlined on slide two, I would like to remind you that today's discussion will contain forward-looking statements that involve risk and uncertainties. These risks and uncertainties are outlined in today's press release and in the company's recent filings with the Securities and Exchange Commission, which we encourage you to read. Our actual results may differ materially from what is discussed on today's call. With that, I'll now turn the call over to Jean-Pierre. Thank you, Joné. Good afternoon, everyone, and than...